Plc's (AMRN) Buy Rating Reiterated at HC Wainwright

Cornelia Mascio
Agosto 13, 2017

Analysts expect that Amarin Corporation PLC will post ($0.22) EPS for the current fiscal year. Three analysts have issued estimates for Amarin Corporation PLC's earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.06). The analysts estimated mean EPS at -0.03. Analysts set a 12-month price target of $7.6 a share. Amarin Corporation plc (ADR) (NASDAQ:AMRN) has risen 76.19% since August 9, 2016 and is uptrending. The company had revenue of $44.95 million for the quarter, compared to the consensus estimate of $40.35 million. During the same quarter in the previous year, the firm earned ($0.07) earnings per share. AMRN generated revenue of $0 in the same quarter, one year ago.

Other equities analysts have also recently issued research reports about the company.

Wall Street analysts are predicting that Amarin Corp Ads (NASDAQ:AMRN) will report earnings per share of $-0.05 in their quarterly report. The stock of Amarin Corporation plc (ADR) (NASDAQ:AMRN) earned "Buy" rating by H.C. Wainwright on Thursday, August 3. HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Amarin Corporation PLC in a research report on Thursday, June 1st. Zacks Investment Research lowered Amarin Co. plc from a "buy" rating to a "hold" rating in a research note on Monday. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $10.00 price target on shares of Amarin Corporation PLC in a research report on Monday, June 26th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. Amarin Corporation PLC now has a consensus rating of "Buy" and an average target price of $7.35.

Amarin Corporation PLC (AMRN) traded down 3.71% during mid-day trading on Wednesday, hitting $3.37. The company's market cap is $1 Billion, and the average volume is 2.4 Million. Oracle Invest Mgmt Inc invested 4.05% in Amarin Corporation plc (ADR) (NASDAQ:AMRN).

The closing price represents the final price that a stock is traded for on a trading day. Stock's twelve month price oscillated between $4.47 and $2.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Note the stock price at publication ($3.26), since the technical rating is based on intraday stock prices.

A number of hedge funds have recently bought and sold shares of AMRN. Quantitative Investment Management LLC boosted its stake in Amarin Corporation PLC by 105.1% in the first quarter. JPMorgan Chase & Co. now owns 278,134 shares of the biopharmaceutical company's stock worth $1,121,000 after buying an additional 242,544 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in Amarin Corporation PLC by 1.4% in the first quarter. Renaissance Technologies LLC now owns 1,730,200 shares of the biopharmaceutical company's stock worth $5,537,000 after buying an additional 1,344,200 shares in the last quarter. Renaissance Technologies LLC boosted its position in Amarin Corporation PLC by 348.2% in the first quarter. Wells Fargo & Company MN now owns 37,801 shares of the biopharmaceutical company's stock valued at $152,000 after buying an additional 5,000 shares during the period. California Public Employees Retirement System now owns 533,300 shares of the biopharmaceutical company's stock worth $1,707,000 after buying an additional 62,800 shares during the period. Finally, Airain ltd raised its position in Amarin Corporation PLC by 382.9% in the second quarter. Oracle Investment Management Inc owns 7.94 million shares or 4.05% of their U.S. portfolio. Insiders own 3.72% of the company's stock.

COPYRIGHT VIOLATION NOTICE: This report was published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this news story on another domain, it was copied illegally and republished in violation of USA & global copyright and trademark legislation.

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE